

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Artini Holdings Limited

雅天妮集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 789)

VOLUNTARY ANNOUNCEMENT IN RELATION TO ENTERING INTO THE STRATEGIC COOPERATION AGREEMENT WITH BAIYUNSHAN WEI YI

This announcement is made by Artini Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to the shareholders of the Company (the “**Shareholders**”) and potential investors of the Company.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that on 19 September 2025, the Company and Guangzhou Baiyunshan Wei Yi Industries Co., Ltd. (廣州白雲山維一實業股份有限公司) (“**Baiyunshan Wei Yi**”) signed a strategic cooperation agreement (the “**Cooperation Agreement**”) to jointly develop products in the big healthcare sector and expand markets (the “**Strategic Cooperation**”), with a cooperation term of one year.

Baiyunshan Wei Yi is one of the subsidiaries of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, a company listed on the Shanghai Stock Exchange (stock code: 600332) and the Main Board of The Stock Exchange of Hong Kong Limited (stock code: 874) respectively, focusing on the big healthcare industry.

According to the Cooperation Agreement, the proposed Strategic Cooperation between the Group and Baiyunshan Wei Yi mainly includes the following aspects:

1. **Joint Product R&D:** The parties will jointly conduct R&D on innovative products focusing on the big healthcare sector, including natural plant extracts, functional health supplements and personal care products.
2. **Market Expansion:** The parties intend to launch jointly developed products and related existing products to overseas markets. Baiyunshan Wei Yi will provide the Group with brand marketing support, including brand strategy, brand tactics and trademark licensing. It will also provide the Group with technical consulting, product promotion and marketing coaching services related to the sales and marketing of big healthcare products.

REASONS FOR AND BENEFITS OF THE STRATEGIC COOPERATION

The Group has actively expanded its skincare and health product sales business in recent years. The Strategic Cooperation intention reached with Baiyunshan Wei Yi aligns with the Group's business development strategy and long-term deployment in the big healthcare industry. The Board believes that the Strategic Cooperation will leverage the Group's advantages in international markets and sales platforms with Baiyunshan Wei Yi's technological, brand and product strengths to achieve synergistic effects. It is expected to enrich the Group's product portfolio, enhance its core competitiveness in the big healthcare sector, and open up new revenue streams. Therefore, the Board believes that signing the Cooperation Agreement with Baiyunshan Wei Yi is in the interests of the Company and its shareholders as a whole.

GENERAL

The Board would like to emphasize that the Cooperation Agreement is non-legally binding. As at the date of this announcement, neither party has entered into any formal or legally binding agreement in relation to the Strategic Cooperation. Therefore, the Strategic Cooperation may or may not proceed. If the Company enters into any formal agreement regarding to the Strategic Cooperation, the Company will make further announcement in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited in due course.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when dealing in the securities of the Company.

By order of the Board
Artini Holdings Limited
Chen Long
Chairman and executive Director

Hong Kong, 19 September 2025

As at the date of this announcement, the executive directors are Mr. Chen Long (Chairman) and Mr. Chen Shaojia (Chief Executive); and the independent non-executive directors are Mr. Yuen Wai Kin, Ms. Ji Lingzi and Mr. Ma Sai Yam.